ADDED
Our business substantially depends upon the successful clinical development of drug candidates using our AP3 platform.
Overview We are a clinical-stage biopharmaceutical company discovering and developing precision medicines utilizing our proprietary Generative Phosphoproteomics Acrivon Predictive Precision Proteomics, or AP3, platform designed to quantify compound-specific, drug-regulated pathway activity levels inside the intact cell in an unbiased manner, yielding terabytes of proprietary data and delivering rapid, actionable insights.
Our company name, Acrivon, is derived from Greek for accurate or precise .
We chose it to embody how our AP3 platform can, among other highly actionable discovery and development applications, accurately match our therapies with patients who will benefit.
Our approach is designed to overcome the limitations of genetics-based precision medicine.
We do this by using our precision medicine platform, AP3, to discover and develop our pipeline of innovative oncology drug candidates.
AP3 is engineered to measure compound-specific effects on the entire tumor cell protein, signaling network and drug-induced resistance mechanisms in an unbiased manner and is modality and disease agnostic.
Our AP3 approach is proteomics-based and designed for direct protein measurement of critical tumor-driving pathways and independent of underlying genetic alterations.
By applying our highly specific patient selection approach, and other AP3 applications, to drug development, we seek to both accelerate clinical development and significantly increase the probability of successful treatment outcomes for patients.
Our pipeline includes our Phase 2b lead program, ACR-368, also known as prexasertib, a precision oncology asset in-licensed from Eli Lilly Company, or Lilly, that targets CHK1 and CHK2, or CHK1/2.
REMOVED
Our business substantially depends upon the successful clinical development of drug candidates using our AP3 platform and OncoSignature , or OncoSignature companion diagnostics.
Overview We are a clinical stage biopharmaceutical company discovering and developing precision oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing our proprietary Generative Phosphoproteomics platform, Acrivon Predictive Precision Proteomics, or AP3.
Our approach is designed to overcome the limitations of genomics-based patient selection methods.
We do this by using our precision medicine platform, AP3, to develop our pipeline of oncology drug candidates.
AP3 is engineered to measure compound-specific effects on the entire tumor cell protein signaling network and drug-induced resistance mechanisms in an unbiased manner.
These distinctive capabilities enable AP3 s direct application for drug design optimization for monotherapy activity, the identification of rational drug combinations, and the creation of drug-specific proprietary OncoSignature companion diagnostics that are used to identify the patients most likely to benefit from Acrivon s drug candidates, which we refer to as patient responders.
We are currently advancing our lead candidate, ACR-368, a selective small molecule inhibitor which targets CHK1 and CHK2 at sub single-digit nM and single-digit nM potency in intact cells, respectively, in a potentially registrational Phase 2 trial focusing on patients with endometrial cancer.
We are continuing enrollment and dosing of patients in this multi-center trial based on AP3-predicted sensitivity to ACR-368 in patients with endometrial adenocarcinoma, a tumor type that was predicted to be sensitive to ACR-368 prior to clinical entry through preclinical AP3-based indication finding, and not previously evaluated in past clinical trials.
Our ACR-368 OncoSignature test, which has not yet obtained regulatory approval, has been extensively evaluated in preclinical studies, including in two separate, blinded, prospectively-designed studies on pretreatment tumor biopsies collected from patients with ovarian cancer treated with ACR-368 in past Phase 2 clinical trials conducted by Eli Lilly and Company, or Lilly, and at the National Cancer Institute, or NCI, providing evidence of robust enrichment of responders through our method.
Moreover, clinical data from the ongoing registrational intent trial in endometrial cancer showed initial validation of the ACR-368 OncoSignature for prospective patient selection (see further details below).